APC and hepatocellular carcinoma: Wnt/β-catenin pathway activity is observed in up to 50% of tumors from patients with HCC, with mutations mostly occurring in CTNNB1 (26–37%), AXIN1/2 (8–10%), and APC (3–5%)9–12.